2025 Q4 -tulosraportti
Vain PDF
25 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 898 | - | - | ||
| 1 403 | - | - | ||
| 20 000 | - | - | ||
| 8 000 | - | - | ||
| 12 000 | - | - |
Ylin
0,057VWAP
Alin
0,037VaihtoMäärä
8 168 536 698
VWAP
Ylin
0,057Alin
0,037VaihtoMäärä
8 168 536 698
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 168 536 698 | 168 536 698 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 168 536 698 | 168 536 698 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 11.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 5.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenEpisurf Medical B (EPIS B) is currently undergoing a significant transformation. Here is a summary of the most important news and outlook based on the latest reports from early 2026: Latest news (Q4 2025 and 2026) • Strategic change: During 2025, the company has implemented a comprehensive shift by combining its medical business with the acquisition of real estate assets. This has led to Torvinge Fastigheter becoming a new major owner with 7.8 % of the capital. • Financial improvement: In the annual report for 2025, the company reported increased order intake (up 13 % in Q4) and increased revenues, while operating costs were significantly reduced compared to the previous year. • Management changes: Episurf announced a new CEO in January 2026, with further management changes taking effect on February 11, 2026. • Capital changes: The number of shares has increased sharply after the exercise of subscription options (series TO14 B) and directed issues in February 2026, which has provided the company with new capital. Future outlook • USA market: The company has recently received patent approval in the USA for its Episealer® MTP implant (big toe), which provides protection in the American market. Commercial launch of this implant in the USA has taken longer than expected, but is a key driver for future growth. • Product range: The focus going forward is on commercialization of the Episealer® Patellofemoral System (kneecap), which has already received FDA approval. • Analyst assessment: The analysis firm Redeye has previously adjusted down its estimates due to restructuring in Europe, but now sees signs of stabilization through cost cuts and a new strategy. • Technical analysis: The stock has broken a falling trend channel, which may indicate a weaker rate of decline or bottom formation, with support around 0.03 SEK.·4 t sittenI believe that this stock will increase in the future
·1 päivä sittenOk. Ran a query in Gemini (Google's AI service) to seek more clarity on what is or is not and is still being reviewed in the USA. Then I get this as an answer: For investors following Episurf Medical, the regulatory development at the US Food and Drug Administration FDA is the most central factor for the company's valuation. Here is a review of what is approved, what is under review, and the status of the clinical studies: ### 1. Marketing Approval (510(k)-clearance) This means that the product can be sold and marketed commercially in the USA. * **Approved: Episealer® Patellofemoral System.** At the end of 2022, Episurf received 510(k)-clearance for this system. It is a patient-specific implant for patients with osteoarthritis in the patellofemoral joint. This was the company's first product approval on the American market and marked an important step from only treating local cartilage damage to also addressing osteoarthritis. ### 2. Products under ongoing review These products are in the regulatory process to obtain market approval in the USA. * **Under review: Episealer® MTP-implant.** This is an implant for the big toe joint (intended to treat hallux rigidus). The company submitted its 510(k)-application and expects approval during 2025/2026. On February 25, 2026, the company announced that they had obtained a new patent in the USA for this implant, which is part of the preparations for the planned market launch. ### 3. Clinical studies (IDE process) For certain products, FDA requires more extensive clinical data before a final market approval can be granted. * **Approved study (IDE): Episealer® Knee System.** FDA has granted a so-called IDE approval (Investigational Device Exemption), which allows Episurf to conduct the clinical study **EPIC-Knee** in the USA. * **Status:** The study is a prospective, randomized, and controlled multicenter study comparing the Episealer implant against microfracture for the treatment of isolated cartilage lesions in the knee joint. Patient recruitment is ongoing at clinics in both USA and Europe. The results from this study will later form the basis for an application for full market approval (PMA) for the knee implant in the USA. ### Summary of the situation: Product,Status with FDA,Market potential Episealer® Patellofemoral,Approved (510k),Commercial sales ongoing. Episealer® MTP (Big toe),Under review,Expected approval 2025/2026. Episealer® Knee (Knee),Clinical study (IDE),Long-term project based on EPIC-Knee.
·10.2.Then just go bankrupt for h...... Then we'll be free from speculating more in that crap.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
25 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenEpisurf Medical B (EPIS B) is currently undergoing a significant transformation. Here is a summary of the most important news and outlook based on the latest reports from early 2026: Latest news (Q4 2025 and 2026) • Strategic change: During 2025, the company has implemented a comprehensive shift by combining its medical business with the acquisition of real estate assets. This has led to Torvinge Fastigheter becoming a new major owner with 7.8 % of the capital. • Financial improvement: In the annual report for 2025, the company reported increased order intake (up 13 % in Q4) and increased revenues, while operating costs were significantly reduced compared to the previous year. • Management changes: Episurf announced a new CEO in January 2026, with further management changes taking effect on February 11, 2026. • Capital changes: The number of shares has increased sharply after the exercise of subscription options (series TO14 B) and directed issues in February 2026, which has provided the company with new capital. Future outlook • USA market: The company has recently received patent approval in the USA for its Episealer® MTP implant (big toe), which provides protection in the American market. Commercial launch of this implant in the USA has taken longer than expected, but is a key driver for future growth. • Product range: The focus going forward is on commercialization of the Episealer® Patellofemoral System (kneecap), which has already received FDA approval. • Analyst assessment: The analysis firm Redeye has previously adjusted down its estimates due to restructuring in Europe, but now sees signs of stabilization through cost cuts and a new strategy. • Technical analysis: The stock has broken a falling trend channel, which may indicate a weaker rate of decline or bottom formation, with support around 0.03 SEK.·4 t sittenI believe that this stock will increase in the future
- ·1 päivä sittenOk. Ran a query in Gemini (Google's AI service) to seek more clarity on what is or is not and is still being reviewed in the USA. Then I get this as an answer: For investors following Episurf Medical, the regulatory development at the US Food and Drug Administration FDA is the most central factor for the company's valuation. Here is a review of what is approved, what is under review, and the status of the clinical studies: ### 1. Marketing Approval (510(k)-clearance) This means that the product can be sold and marketed commercially in the USA. * **Approved: Episealer® Patellofemoral System.** At the end of 2022, Episurf received 510(k)-clearance for this system. It is a patient-specific implant for patients with osteoarthritis in the patellofemoral joint. This was the company's first product approval on the American market and marked an important step from only treating local cartilage damage to also addressing osteoarthritis. ### 2. Products under ongoing review These products are in the regulatory process to obtain market approval in the USA. * **Under review: Episealer® MTP-implant.** This is an implant for the big toe joint (intended to treat hallux rigidus). The company submitted its 510(k)-application and expects approval during 2025/2026. On February 25, 2026, the company announced that they had obtained a new patent in the USA for this implant, which is part of the preparations for the planned market launch. ### 3. Clinical studies (IDE process) For certain products, FDA requires more extensive clinical data before a final market approval can be granted. * **Approved study (IDE): Episealer® Knee System.** FDA has granted a so-called IDE approval (Investigational Device Exemption), which allows Episurf to conduct the clinical study **EPIC-Knee** in the USA. * **Status:** The study is a prospective, randomized, and controlled multicenter study comparing the Episealer implant against microfracture for the treatment of isolated cartilage lesions in the knee joint. Patient recruitment is ongoing at clinics in both USA and Europe. The results from this study will later form the basis for an application for full market approval (PMA) for the knee implant in the USA. ### Summary of the situation: Product,Status with FDA,Market potential Episealer® Patellofemoral,Approved (510k),Commercial sales ongoing. Episealer® MTP (Big toe),Under review,Expected approval 2025/2026. Episealer® Knee (Knee),Clinical study (IDE),Long-term project based on EPIC-Knee.
- ·10.2.Then just go bankrupt for h...... Then we'll be free from speculating more in that crap.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 898 | - | - | ||
| 1 403 | - | - | ||
| 20 000 | - | - | ||
| 8 000 | - | - | ||
| 12 000 | - | - |
Ylin
0,057VWAP
Alin
0,037VaihtoMäärä
8 168 536 698
VWAP
Ylin
0,057Alin
0,037VaihtoMäärä
8 168 536 698
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 168 536 698 | 168 536 698 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 168 536 698 | 168 536 698 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 11.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 5.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
25 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 11.7.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 5.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenEpisurf Medical B (EPIS B) is currently undergoing a significant transformation. Here is a summary of the most important news and outlook based on the latest reports from early 2026: Latest news (Q4 2025 and 2026) • Strategic change: During 2025, the company has implemented a comprehensive shift by combining its medical business with the acquisition of real estate assets. This has led to Torvinge Fastigheter becoming a new major owner with 7.8 % of the capital. • Financial improvement: In the annual report for 2025, the company reported increased order intake (up 13 % in Q4) and increased revenues, while operating costs were significantly reduced compared to the previous year. • Management changes: Episurf announced a new CEO in January 2026, with further management changes taking effect on February 11, 2026. • Capital changes: The number of shares has increased sharply after the exercise of subscription options (series TO14 B) and directed issues in February 2026, which has provided the company with new capital. Future outlook • USA market: The company has recently received patent approval in the USA for its Episealer® MTP implant (big toe), which provides protection in the American market. Commercial launch of this implant in the USA has taken longer than expected, but is a key driver for future growth. • Product range: The focus going forward is on commercialization of the Episealer® Patellofemoral System (kneecap), which has already received FDA approval. • Analyst assessment: The analysis firm Redeye has previously adjusted down its estimates due to restructuring in Europe, but now sees signs of stabilization through cost cuts and a new strategy. • Technical analysis: The stock has broken a falling trend channel, which may indicate a weaker rate of decline or bottom formation, with support around 0.03 SEK.·4 t sittenI believe that this stock will increase in the future
- ·1 päivä sittenOk. Ran a query in Gemini (Google's AI service) to seek more clarity on what is or is not and is still being reviewed in the USA. Then I get this as an answer: For investors following Episurf Medical, the regulatory development at the US Food and Drug Administration FDA is the most central factor for the company's valuation. Here is a review of what is approved, what is under review, and the status of the clinical studies: ### 1. Marketing Approval (510(k)-clearance) This means that the product can be sold and marketed commercially in the USA. * **Approved: Episealer® Patellofemoral System.** At the end of 2022, Episurf received 510(k)-clearance for this system. It is a patient-specific implant for patients with osteoarthritis in the patellofemoral joint. This was the company's first product approval on the American market and marked an important step from only treating local cartilage damage to also addressing osteoarthritis. ### 2. Products under ongoing review These products are in the regulatory process to obtain market approval in the USA. * **Under review: Episealer® MTP-implant.** This is an implant for the big toe joint (intended to treat hallux rigidus). The company submitted its 510(k)-application and expects approval during 2025/2026. On February 25, 2026, the company announced that they had obtained a new patent in the USA for this implant, which is part of the preparations for the planned market launch. ### 3. Clinical studies (IDE process) For certain products, FDA requires more extensive clinical data before a final market approval can be granted. * **Approved study (IDE): Episealer® Knee System.** FDA has granted a so-called IDE approval (Investigational Device Exemption), which allows Episurf to conduct the clinical study **EPIC-Knee** in the USA. * **Status:** The study is a prospective, randomized, and controlled multicenter study comparing the Episealer implant against microfracture for the treatment of isolated cartilage lesions in the knee joint. Patient recruitment is ongoing at clinics in both USA and Europe. The results from this study will later form the basis for an application for full market approval (PMA) for the knee implant in the USA. ### Summary of the situation: Product,Status with FDA,Market potential Episealer® Patellofemoral,Approved (510k),Commercial sales ongoing. Episealer® MTP (Big toe),Under review,Expected approval 2025/2026. Episealer® Knee (Knee),Clinical study (IDE),Long-term project based on EPIC-Knee.
- ·10.2.Then just go bankrupt for h...... Then we'll be free from speculating more in that crap.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 898 | - | - | ||
| 1 403 | - | - | ||
| 20 000 | - | - | ||
| 8 000 | - | - | ||
| 12 000 | - | - |
Ylin
0,057VWAP
Alin
0,037VaihtoMäärä
8 168 536 698
VWAP
Ylin
0,057Alin
0,037VaihtoMäärä
8 168 536 698
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 168 536 698 | 168 536 698 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 168 536 698 | 168 536 698 | 0 | 0 |